Literature DB >> 26040253

Prototheca wickerhamii algaemia: an emerging infection in solid organ transplant recipients.

T D Bandaranayake1, A Paniz Mondolfi2, D R Peaper2, M F Malinis1.   

Abstract

Prototheca wickerhamii is an alga that rarely causes human disease but has been reported increasingly among immunocompromised individuals. We report a fatal case of P. wickerhamii in a renal transplant recipient who presented with a cutaneous lesion that led to disseminated disease despite treatment with voriconazole. We reviewed previous cases of protothecosis involving solid organ transplant recipients in the literature and discussed the value of newer microbiology platforms, i.e., matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), to achieve early diagnosis and impact outcomes.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MALDI-TOF; Prototheca wickerhamii; algaemia; solid organ transplant

Mesh:

Year:  2015        PMID: 26040253     DOI: 10.1111/tid.12407

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

1.  Answer to August 2018 Photo Quiz.

Authors:  Poornima Ramanan; Abinash Virk; Jennifer M Boland; Bobbi Pritt; Marco Rizzo; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Successful treatment of cutaneous protothecosis with liposomal amphotericin and oral itraconazole.

Authors:  Brendan McMullan; Simon Pollett; Chayanika Biswas; Donald Packham
Journal:  Med Mycol Case Rep       Date:  2016-08-03

3.  Protothecosis in the mucosa of the pharynx mimicking pharyngeal cancer in an immunocompetent individual: a case report.

Authors:  Marie Yamashita; Mahoko Ikeda; Ito Kato; Yuki Ohama; Mizuo Ando; Masako Ikemura; Daisuke Jubishi; Yoshiaki Kanno; Koh Okamoto; Takashi Umeyama; Shigeki Nakamura; Yoshitsugu Miyazaki; Shu Okugawa; Kyoji Moriya
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-02-14       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.